CHEK vs. COEP, SRNE, IMNN, NXGL, MNPR, OTRK, TNXP, BSGM, MBOT, and SNTI
Should you be buying Check-Cap stock or one of its competitors? The main competitors of Check-Cap include Coeptis Therapeutics (COEP), Sorrento Therapeutics (SRNE), Imunon (IMNN), NEXGEL (NXGL), Monopar Therapeutics (MNPR), Ontrak (OTRK), Tonix Pharmaceuticals (TNXP), BioSig Technologies (BSGM), Microbot Medical (MBOT), and Senti Biosciences (SNTI). These companies are all part of the "medical" sector.
Coeptis Therapeutics (NASDAQ:COEP) and Check-Cap (NASDAQ:CHEK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
Check-Cap received 365 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Coeptis Therapeutics an outperform vote while only 66.07% of users gave Check-Cap an outperform vote.
Coeptis Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 831.68%. Given Check-Cap's stronger consensus rating and higher possible upside, research analysts clearly believe Coeptis Therapeutics is more favorable than Check-Cap.
Check-Cap has lower revenue, but higher earnings than Coeptis Therapeutics. Check-Cap is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.
Coeptis Therapeutics' return on equity of -47.85% beat Check-Cap's return on equity.
13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 21.5% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Coeptis Therapeutics has a beta of -0.89, suggesting that its stock price is 189% less volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.
In the previous week, Coeptis Therapeutics had 2 more articles in the media than Check-Cap. MarketBeat recorded 5 mentions for Coeptis Therapeutics and 3 mentions for Check-Cap. Coeptis Therapeutics' average media sentiment score of 0.79 beat Check-Cap's score of 0.13 indicating that Check-Cap is being referred to more favorably in the news media.
Summary
Coeptis Therapeutics beats Check-Cap on 10 of the 16 factors compared between the two stocks.
Get Check-Cap News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHEK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Check-Cap Competitors List
Related Companies and Tools
